Becton Dickinson and Co (BDX) Shares Sold by NN Investment Partners Holdings N.V.

NN Investment Partners Holdings N.V. lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 5.3% during the 3rd quarter, Holdings Channel reports. The firm owned 55,820 shares of the medical instruments supplier’s stock after selling 3,154 shares during the period. NN Investment Partners Holdings N.V.’s holdings in Becton Dickinson and were worth $14,570,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BDX. Clarus Wealth Advisors acquired a new position in Becton Dickinson and in the second quarter valued at about $188,000. Gulf International Bank UK Ltd lifted its stake in Becton Dickinson and by 2.6% in the second quarter. Gulf International Bank UK Ltd now owns 85,890 shares of the medical instruments supplier’s stock valued at $20,575,000 after buying an additional 2,150 shares during the period. Bath Savings Trust Co lifted its stake in Becton Dickinson and by 145.8% in the second quarter. Bath Savings Trust Co now owns 10,856 shares of the medical instruments supplier’s stock valued at $2,601,000 after buying an additional 6,439 shares during the period. DnB Asset Management AS lifted its stake in Becton Dickinson and by 4.8% in the second quarter. DnB Asset Management AS now owns 32,578 shares of the medical instruments supplier’s stock valued at $7,804,000 after buying an additional 1,500 shares during the period. Finally, Community Bank & Trust Waco Texas acquired a new position in Becton Dickinson and in the second quarter valued at about $272,000. Institutional investors own 92.57% of the company’s stock.

BDX has been the topic of several analyst reports. KeyCorp reissued a “buy” rating and issued a $264.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Wells Fargo & Co increased their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $255.40.

NYSE BDX opened at $230.50 on Thursday. The stock has a market cap of $61.70 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 1.37 and a beta of 1.11. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a one year low of $203.99 and a one year high of $265.87.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter last year, the firm posted $2.46 earnings per share. Becton Dickinson and’s revenue was up 41.0% compared to the same quarter last year. Research analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Technical Analysis of Stocks, How Can It Help

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply